Latest Immunosuppressants Stories
HORSHOLM, Denmark, Dec. 19, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) (Veloxis) today issued the following statement regarding an order issued by the U.S.
ReportsandReports.com adds latest reports on Adalimumab Industry for Global and China Markets to its store. DALLAS, Dec.
First Presentation of Phase 3 Data From Brodalumab Psoriasis Program THOUSAND OAKS, Calif. and LONDON, Dec.
FIRST OF SEVERAL PHASE 3 TRIALS TO REPORT RESULTS INDIANAPOLIS, Dec.
SAN FRANCISCO, Dec.
- Update on complete remissions with personalized cell therapy CTL019 in patients with relapsed/refractory acute lymphoblastic leukemia EAST HANOVER, N.J., Dec.
DALLAS, December 1, 2014 /PRNewswire/ -- ReportsnReports.com adds EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2023 market research on the autoimmune
Study Met All Primary Endpoints Against Stelara® (ustekinumab) and Placebo THOUSAND OAKS, Calif. and LONDON, Nov.
However, Platform Injectables Continue to Represent the Majority of Recent MS Prescriptions, According to Findings from Decision Resources Group BURLINGTON, Mass., Nov.
- A transitional zone between two communities containing the characteristic species of each.